Raisio acquired Benecol business from affiliates of Johnson

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Raisio acquired Benecol business from affiliates of Johnson & Johnson

Raisio plc, Stock Exchange Release 19 November 2014, at 8.30 a.m. Finnish time

Effective 19 November 2014, Raisio Group acquired the Benecol business in the UK, Ireland and Belgium from Cilag GmbH International and amended its agreement concerning North American rights to Benecol with McNEIL-PPC, Inc. Both Cilag GmbH International and McNEIL-PPC, Inc. are part of the Johnson & Johnson Family of Companies. In the UK and Ireland, Benecol is the market leader in cholesterol-lowering functional foods. The acquisition is estimated to increase Raisio’s EBIT by some 9 million euros annually.

“Benecol is a globally well-known cholesterol-lowering functional food brand owned by Raisio. The acquisition of the Benecol business in the UK, Ireland and Belgium as well as the amended agreement in the USA strongly support Raisio’s growth strategy with its branded business. In terms of Benecol products, Raisio’s long-term strategic goal is to enhance competitiveness in the existing markets, to expand into new markets as well as to innovate new products. Through this arrangement, we will have the opportunity to develop Benecol business on our own terms, following our strategic objectives,” says Raisio plc’s CEO Matti Rihko.

Cilag GmbH International has had the exclusive right to sell and market Benecol products in the UK, Ireland and Belgium. With the acquisition, rights to the Benecol trademark and plant stanol ester patents held by Cilag GmbH International will return to Raisio. The US business is included in the deal, but McNEIL-PPC, Inc. will continue as Raisio’s licensee for the time being. The amended agreement allows for the return of the Benecol rights and transfer of certain US assets to Raisio or its possible new licensee at a later date. For the first time since 1997, Raisio will have all the rights to the Benecol brand and plant stanol ester, the Benecol product ingredient. This allows Raisio to develop the business globally on a new basis.

The purchase price for the business and stocks totalled EUR 88.4 million, which was paid as the object of the deal transferred to Raisio. The completion of the deal does not require an approval from the competition authorities. Raisio financed the acquisition by a long-term loan of EUR 80 million.

This arrangement meets the criteria that Raisio has set on its acquisitions and is in line with the company’s vision focusing on healthy and ecological snacks. Furthermore, EBITDA/EV factor is also in accordance with Raisio’s acquisition policy.

Majority of the purchase price is allocated to intangible assets. On 30 September 2014, goodwill amounted to EUR 116 million on Raisio’s consolidated balance sheet. With the deal, it will increase by approximately EUR 53 million. The Group’s equity ratio will be approximately 58 per cent when the acquisition is completed. Raisio’s equity ratio was 70 per cent on 30 September 2014. Acquisition-related costs of approximately EUR 0.7 million will be recorded as a one-off item in the fourth quarter of 2014.

With the acquisition of the Benecol business in Europe, a few employees will join Raisio in the UK. In 2013, net sales of Benecol in the acquired European countries and USA were approximately EUR 76 million, of which the UK and Ireland accounted for some 85 per cent. In the UK and Ireland, Benecol products are market leaders in cholesterol-lowering functional foods.  

Plant stanol ester of Benecol products has been chosen one of the world’s most significant nutritional innovations. Benecol products are sold in almost 30 countries on five continents. Benecol® is Raisio’s trademark and plant stanol ester the company’s widely patented ingredient of Benecol products. Benecol products account for about a fifth of the total consumer market for cholesterol-lowering functional foods worth approximately one billion euros.

RAISIO PLC

Heidi Hirvonen Communications and IR Manager                                                                                       tel. +358 50 567 3060

Further information: Matti Rihko, Raisio CEO, tel. +358 400 830 727

Raisio Group briefly

Raisio plc is an international specialist in plant-based nutrition. Raisio’s operations are divided into two divisions: Brands and Raisioagro. The Group’s key market areas are Finland, Great Britain, the Czech Republic, Russia, Ukraine, Poland, Estonia and Sweden. Raisio plc’s shares are listed on NASDAQ OMX Helsinki Ltd. In 2013, the Group's net sales totalled EUR 558 million and EBIT was EUR 39 million. The Group employs some 1,900 people. Raisio’s best-known brands are Benecol, Honey Monster, Elovena, Fox’s, Dormen, Juicee Gummee, Poppets and Benemilk.

Distribution NASDAQ OMX Key media www.raisio.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 147

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 92

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Humanoid Robots Need Results Before 2035 Hype Peaks

Updated Category News Views 245

A robot climbing stairs is neat; a robot finishing Tuesday’s shift is the investment case. The latest humanoid robotics forecast puts the global market at $3.07 billion in 2026, up from $2.26 billion in 2025, and projects $47.49 billion by 2035. That is a 35.59% compound annual growth rate, the kind of number that makes investors sit up straight. It also demands a...

Continue Reading
Health In Tech Brings a Tech Veteran Onto Its Board

Updated Category News Views 115

Board appointments rarely make the cash register ring, but they can tell you where management thinks the next bruises are coming from. Health In Tech has added Tim Cortes as an independent director, put him in charge of the Compensation Committee, and placed him on both the Audit and Nominating and Corporate Governance Committees. For an AI-enabled insurance technology...

Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 168

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 254

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 158

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading
Peñoles Locks In Solar Storage for Northern Mine Loads

Updated Category News Views 54

A mine never sleeps, which is why the battery matters more than the solar-panel headline. Peñoles has signed a 20-year power-supply agreement with Atlas Renewable Energy for a Coahuila project combining 269 MWp of solar generation with battery storage. The project is slated to begin operating in the first half of 2029 and is expected to provide roughly 550 GWh a year to...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 68

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading
Workday’s EU Cloud Move Raises the Sovereignty Bar Again

Updated Category News Views 124

Europe’s sovereignty squeeze just got a lot more concrete for Workday. The company is taking its EU Sovereign Cloud beyond the usual data-residency talking points by planning an Ireland-based operating company, European leadership, and governance intended to keep decisions on the service and customer data inside Europe. For a platform sitting underneath payroll, HR...

Continue Reading

Top 5 Most Recently Viewed Articles

Hepsiburada's Impressive Q3 2025 Performance Review

Updated Category News Views 281

Hepsiburada Reports Significant Gains in Q3 2025 Hepsiburada, officially known as D-MARKET Electronic Services & Trading (NASDAQ: HEPS), has unveiled robust financial results for the third quarter of 2025. The Turkish e-commerce giant reported an impressive increase in gross merchandise value (GMV) and revenue, highlighting the company's operational resilience in a...

Continue Reading
Fulcrum Therapeutics Faces Challenges Amid Sickle Cell Trials

Updated Category News Views 212

Market Moves and Stock Reactions So, let’s get straight to the meat of it. Fulcrum Therapeutics Inc. (NASDAQ:FULC) took a nosedive recently—down about 10%—right after they dropped the latest news on their Phase 1b trial for pociredir aimed at treating sickle cell disease. Stock fell to around $9.80, and honestly, if you're still holding shares, well, it's time to...

Continue Reading
SBM Offshore's Share Repurchase Program Insights and Updates

Updated Category News Views 215

Overview of SBM Offshore’s Share Repurchase Program SBM Offshore has recently conducted a significant share repurchase program amounting to EUR141 million (approximately US$150 million). This initiative began on April 24, 2025, and aims to reduce share capital while also supporting management and employee share programs. The program has been designed to both enhance...

Continue Reading
Plymouth Industrial REIT Responds to Acquisition Proposal

Updated Category News Views 212

Plymouth Industrial REIT Receives Unsolicited Acquisition Proposal Plymouth Industrial REIT, Inc. (NYSE: PLYM), a leader in the industrial real estate sector, recently attracted attention with an unsolicited and non-binding acquisition proposal. This proposal comes from Sixth Street Partners, LLC, and suggests a price of $24.10 per share for all outstanding shares of the...

Continue Reading
Middlefield Canadian Income PCC AGM Results Breakdown

Updated Category News Views 230

Overview of the AGM Results for Middlefield Canadian Income PCC Middlefield Canadian Income PCC (the "Company") and Middlefield Canadian Income - GBP PC (the "Cell") have recently concluded their annual general meeting, a significant event that spotlighted the Company's journey and future direction. Conducted with transparency and diligence, this meeting has underscored...

Continue Reading